Oncology News | pharmaphorum

News

ASH: Servier's Tibsovo poised for first-line used in AML

Servier has revealed the full data from its phase 3 trial of Tibsovo as a first-line treatment for acute myeloid leukaemia that it

News

ASH: Gilead, BMS CAR-Ts square off in relapsed lymphoma

A pair of trials have suggested that CAR-T therapies could offer an improved option for patients with large B cell lymphoma (LBCL) who have relapsed after or haven't responded to first-line

News

Roche builds case for TIGIT combo in untreated lung cancer

Roche's closely-watched combination of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq has shown long-term efficacy in an ongoing trial in lung cancer, adding to the evidence

News

Henlius claims win for PD-1 drug in small cell lung cancer

China's Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in a phase 3 trial as first-line therapy for extensive sta

News

AZ, Daiichi take aim at Gilead in triple-negative breast can...

AstraZeneca and Daiichi Sankyo have reported new data with their antibody-drug conjugate for triple-negative breast cancer (TNBC), as they build a case to challenge Gilead's already-markete

News

Merck claims another adjuvant okay from FDA for Keytruda

Merck & Co's strategy of pushing Keytruda earlier in the treatment pathway for cancers has secured anther victory, after the FDA approved the immunotherapy for adjuvant treatment of ski

ASH: Servier's Tibsovo poised for first-line used in AML

ASH: Gilead, BMS CAR-Ts square off in relapsed lymphoma

Roche builds case for TIGIT combo in untreated lung cancer

Henlius claims win for PD-1 drug in small cell lung cancer

AZ, Daiichi take aim at Gilead in triple-negative breast can...

Merck claims another adjuvant okay from FDA for Keytruda

Vanda ends 40-year hiatus for new motion sickness drugs

How to meet your physicians where they are online

News

Editor's Picks